Despite the wealth of new insights into the dysregulated processes underlying the appearance of toxic amyloid plaques and hyperphosphorylated tau protein, treatments targeting these continue to fail to cure AD, and offer only minimal symptomatic relief [6–10]. This evidence concerns the gene MAPT and Alzheimer disease.